Well the title is very appropriate for the company. "Tomorrow Never Dies". No matter how many clinical trials have failed to achieve the primary end point, there's always hope with a new trial. A new indication, a bigger dose given at an earlier time to a different subset of the population... and always only 15 days until something is revealed...
- Forums
- ASX - By Stock
- MSB
- Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel
Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-305
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
95.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.090B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 12540 | $1.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
91.0¢ | 13620 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 12540 | 1.000 |
1 | 1000 | 0.995 |
1 | 1128 | 0.975 |
1 | 1301 | 0.970 |
1 | 52 | 0.955 |
Price($) | Vol. | No. |
---|---|---|
0.910 | 13620 | 3 |
0.925 | 1909 | 5 |
0.950 | 216 | 1 |
0.955 | 6648 | 3 |
0.960 | 4625 | 2 |
Last trade - 10.00am 29/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
Day chart unavailable
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online